A Multicenter, Open-Label, Dose-Escalating Phase I Trial of the DNA-PK Inhibitor MSC2490484A in Subjects With Advanced Solid Tumors or Chronic Lymphocytic Leukemia

Trial Profile

A Multicenter, Open-Label, Dose-Escalating Phase I Trial of the DNA-PK Inhibitor MSC2490484A in Subjects With Advanced Solid Tumors or Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs M 3814 (Primary)
  • Indications Chronic lymphocytic leukaemia; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Merck KGaA
  • Most Recent Events

    • 21 Jun 2017 Planned End Date changed from 1 Nov 2017 to 31 Jul 2019.
    • 21 Jun 2017 Planned primary completion date changed from 1 Nov 2017 to 31 Jul 2019.
    • 02 Jun 2017 Results (n=25) assessing the safety, tolerability, pharmacokinetics and single agent activity of M3814 in patients with solid tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top